Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 1064-1072

  Lu, R N ^a,b   Yang, S ^c   Wu, H M ^c   Zheng, X L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAMTS13 protein, human; Hyperbilirubinemia; Thrombosis; Thrombotic microangiopathies; Von Willebrand factor

Indexed keywords

BILIRUBIN; BILIRUBIN OXIDASE; BILIVERDIN; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; PROTEINASE INHIBITOR;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERBILIRUBINEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BLOOD; DOSE RESPONSE; ENZYMOLOGY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM;

ADAM PROTEINS; ADAMTS13 PROTEIN; BILIRUBIN; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERBILIRUBINEMIA; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEASE INHIBITORS; PROTEOLYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VON WILLEBRAND FACTOR;

EID: 84930181394     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12901     Document Type: Article

References (26)

1. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol 2002; 9: 389-94.
2. Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3: 1702-9.
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
4. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-9.
5. Zheng XL. ADAMTS13. TTP and Beyond. Hereditary Genet 2013; 2: e104.
6. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
7. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-52.
8. Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost 2006; 4: 333-8.
9. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
10. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med 1998; 339: 1585-94.
11. Studt JD, Kremer HJ, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lammle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-4.
12. Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-7.
13. Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1511-8.
14. Zhang L, Lawson HL, Harish VC, Huff JD, Knovich MA, Owen J. Creation of a recombinant peptide substrate for fluorescence resonance energy transfer-based protease assays. Anal Biochem 2006; 358: 298-300.
15. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285: 28596-603.
16. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-94.
17. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005; 280: 29428-34.
18. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-74.
19. Furlan M, Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Bailliere's Clin Haematol 1998; 11: 509-14.
20. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA 2008; 105: 7416-21.
21. Jin SY, Tohyama J, Bauer RC, Cao NN, Rader DJ, Zheng XL. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol 2012; 32: 1817-23.
22. Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol 2011; 31: 2261-9.
23. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 2010; 115: 2300-10.
24. Eckmann CM, De Laaf RT, van Keulen JM, van Mourik JA, De Laat B. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1.
25. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
26. L'Acqua C, Hod E. New perspectives on the thrombotic complications of haemolysis. Br J Haematol 2014; 168: 175-85.